ALK7 Obesity Target: What Roche's $1.16B Rona RNAi Deal Means for Fat-Focused Drug Discovery

For the past few years, the obesity conversation has focused on one question: how much weight can incretin therapies take off? Scientists and dealmakers are now asking another: what if we could change how fat cells handle lipids?

One answer centers on ALK7, a receptor involved in lipid retention in adipocytes, and it just reached a major milestone. On October 13, 2026, Rona Therapeutics announced an agreement granting Roche exclusive worldwide rights to its ALK7-targeting RNAi candidate for obesity and metabolic diseases. Rona evaluated this candidate in Cyagen’s humanized ALK7 mice and NHP ^[1].

The deal includes up to US$100 million in upfront and near-term milestone payments and up to US$1.06 billion in development, regulatory and commercial milestones, plus tiered royalties ^[1]. The candidate uses Rona’s proprietary extrahepatic delivery platform; its code name and development stage remain undisclosed.

Figure 1. Rona Therapeutics enters into global license agreement with Roche ^[1].

The agreement comes just five months after GSK licensed SA030, a long-acting ALK7 siRNA from China-based SiranBio, in a deal valued at more than US$1 billion ^[2]. Together, these deals suggest growing interest in targeting adipose biology to complement treatments that act on appetite. Below, we explore the biology behind ALK7, the companies pursuing it, and how humanized mouse models can support the evaluation of ALK7-targeting RNAi candidates.

What Is ALK7 and How Does It Control Fat Storage?

ALK7 (activin receptor-like kinase 7) is a type I receptor in the TGF-β superfamily, encoded by the ACVR1C gene and found mainly in adipose tissue. When activin ligands such as Activin E (from INHBE) or Activin C (from INHBC) bind to it, ALK7 switches on SMAD2/3 signaling inside the fat cell. The result is reduced lipolysis and more lipid storage. In simple terms, ALK7 acts as a brake on fat burning.

Figure 2. Signaling pathways of ALK7 in adipocytes ^[3].

What makes this brake so interesting is that people appear to do better when it works less well. Large human genetic studies found that ACVR1C coding variants predicted to reduce ALK7 function were associated with a lower BMI-adjusted waist-to-hip ratio and a lower risk of type 2 diabetes ^[4]. Mouse studies tell a similar story, since animals with inactivated ALK7 signaling resist diet-induced obesity.

The cardiometabolic picture has also become clearer. A bidirectional Mendelian randomization study linked genetically higher circulating INHBC to atherogenic dyslipidemia and greater risks of coronary artery disease and fatty liver disease. The same team showed that, in human adipocytes, Activin C signals through ALK7 to suppress lipolysis ^[5]. ALK7 therefore sits at a crossroads of fat distribution, glucose control and heart health.

How ALK7 Inhibition Differs from GLP-1 Therapies

GLP-1 receptor agonists work largely by reducing appetite and food intake. Silencing ALK7 takes a different route, acting directly on fat cells with the aim of reducing fat mass, especially visceral fat, while sparing muscle. That is why many researchers see ALK7 not as a rival to incretins but as a potential partner, one that could improve the quality of weight loss rather than only its quantity.

The first human proof of mechanism arrived in January 2026. Arrowhead Pharmaceuticals reported that a single dose of ARO-ALK7 lowered adipose ALK7 mRNA by a mean of 88% and reduced visceral fat by 14.1% versus placebo at week 8 ^[6]. Lean-mass preservation has so far been shown mainly in animal studies, so larger and longer trials will be watched closely.

Figure 3. ARO-ALK7 induced dose-dependent reductions in adipose ALK7 mRNA ^[7].

Others are moving fast. Alnylam started a Phase 1 study of ALN-2232 in March 2026 ^[8], SA030 is in Phase 1 under the GSK and SiranBio partnership, and Novo Nordisk revealed several ALK7 assets at its September investor day, with the lead expected to reach the clinic this year ^[2]. Roche now joins this group through Rona.

Beyond ALK7: INHBE, GDF8 and Combination Strategies

ALK7 is part of a broader activin signaling network. Activin E, encoded by INHBE and produced mainly in the liver, signals to adipose tissue through ALK7. People carrying loss-of-function INHBE variants tend to have a more favorable fat distribution, and liver-targeted INHBE siRNAs are already in clinical testing ^[6]. Meanwhile, GDF8 (myostatin) inhibition is being studied alongside incretin therapies to help preserve muscle during weight loss. Together, these approaches raise a broader question: which combinations could best address the biology of the liver, fat and muscle?

These strategies also bring different delivery challenges. GalNAc conjugation is an established approach for delivering siRNA to hepatocytes, but directly targeting ALK7 requires efficient delivery to adipocytes. Achieving this with sufficient selectivity and a suitable safety profile remains a key development challenge. The Roche and GSK agreements therefore highlight interest not only in ALK7 biology but also in the delivery technologies needed to reach it. Much of their potential value remains tied to future milestones, reflecting the development and commercial uncertainties still ahead.

Figure 4 .Receptor-mediated delivery strategies and representative siRNA and antisense oligonucleotide programs targeting the liver and extrahepatic tissues ^[9].

Why Humanized ALK7 Mice Matter for RNAi Drug Development

Here is a practical challenge every oligonucleotide team knows well. siRNAs and antisense molecules recognize precise nucleotide sequences, so a candidate designed against human ACVR1C may do nothing to the mouse Acvr1c transcript. Teams then fall back on mouse-specific surrogate sequences, which adds uncertainty at the moment of translation. Humanized mice solve this by replacing the mouse gene with its human counterpart, allowing the actual clinical sequence to be tested in vivo for knockdown, pharmacodynamics, duration of effect and body composition in diet-induced obesity models.

That is exactly the role our huALK7 (ACVR1C) mouse, C001911, played in Rona's preclinical program. In this C57BL/6NCya strain, the mouse Acvr1c sequence from the 5′ UTR to downstream of the 3′ UTR is replaced with the corresponding human ACVR1C sequence. Because both the human coding region and the UTRs are present, researchers can evaluate siRNAs and antisense oligonucleotides wherever they bind on the transcript, as well as antibody approaches against the receptor. We are proud that this model supported a program that has now found a global partner.

Figure 5. Impact of a single subcutaneous administration of positive controls on human ACVR1C mRNA expression in distinct adipose tissues of huALK7(ACVR1C) mice (~7 weeks old, homozygous, male, n=4).

Building on the same huALK7 line, Cyagen has also developed multi-gene models for teams working across the activin axis. The huALK7/huINHBE mouse, Product ID C001994, adds human INHBE so that the liver-to-fat Activin E and ALK7 pathway can be studied as a fully human ligand and receptor pair, and ligand-directed and receptor-directed strategies can be compared in one model. The huGDF8/huALK7/huINHBE mouse, Product ID C002082, further incorporates human MSTN, making it well suited to fat-and-muscle combination studies and to research on body composition, type 2 diabetes and MASLD.

Beyond the models themselves, Cyagen offers end-to-end in vivo pharmacology services for metabolic disease programs. Our team can establish diet-induced obesity and other metabolic disease models in these humanized lines and run efficacy studies on your candidate, covering target knockdown in adipose tissue, body weight, body composition, glucose and lipid parameters, and histopathology. Instead of sourcing animals, building disease models and coordinating studies across multiple vendors, you can bring your molecule to us and receive decision-ready efficacy data from a single partner.

👉 [Explore Our Full Validation Data of huALK7 Mice]

What Comes Next for ALK7

In less than a year, ALK7 has moved from first-in-human data to multiple billion-dollar partnerships. Big questions remain about long-term safety, dosing intervals, combinations with incretins and how well adipose-targeted delivery will scale. The answers will come from the clinic, but they will also depend on preclinical models that faithfully represent the human target. For anyone working on the next generation of obesity medicines, ALK7 is a story worth following closely, and Cyagen is ready to help you move from target to in vivo proof of concept with humanized models and metabolic efficacy studies under one roof.

👉 [Explore Our Comprehensive CRO Solutions for Metabolic Diseases]

👉 [Consult with Our Experts to Design Your Next High-Impact Project]

References

[1] Rona Therapeutics. Rona Therapeutics enters into global license agreement with Roche for ALK7-targeting RNAi therapy for obesity and metabolic diseases [Internet]. PR Newswire; 2026 Oct 13.

[2] Taylor NP. Roche inks $1.2B deal with China's Rona to enter emerging ALK7 obesity race [Internet]. Fierce Biotech; 2026 Oct 13 [cited 2026 Oct 15].

[3] Ongaro L, Bernard DJ. Activin Actions in Adipocytes. J Clin Endocrinol Metab. 2025 Jun 17;110(7):1803-1810. doi: 10.1210/clinem/dgaf233. PMID: 40208114; PMCID: PMC12192441.

[4] Emdin CA, Khera AV, Aragam K, Haas M, Chaffin M, Klarin D, Natarajan P, Bick A, Zekavat SM, Nomura A, Ardissino D, Wilson JG, Schunkert H, McPherson R, Watkins H, Elosua R, Bown MJ, Samani NJ, Baber U, Erdmann J, Gupta N, Danesh J, Saleheen D, Gabriel S, Kathiresan S. DNA Sequence Variation in ACVR1C Encoding the Activin Receptor-Like Kinase 7 Influences Body Fat Distribution and Protects Against Type 2 Diabetes. Diabetes. 2019 Jan;68(1):226-234. doi: 10.2337/db18-0857. Epub 2018 Nov 2. PMID: 30389748; PMCID: PMC6302541.

[5] Loh NY, Rosoff DB, Richmond R, Noordam R, Smith GD, Ray D, Karpe F, Lohoff FW, Christodoulides C. Bidirectional Mendelian Randomization Highlights Causal Relationships Between Circulating INHBC and Multiple Cardiometabolic Diseases and Traits. Diabetes. 2024 Dec 1;73(12):2084-2094. doi: 10.2337/db24-0168. PMID: 39283655; PMCID: PMC11579406.

[6] Arrowhead Pharmaceuticals, Inc. Arrowhead Pharmaceuticals announces interim clinical data on RNAi-based obesity candidates showing weight loss in obese patients with diabetes and improved measures of body composition [Internet]. Pasadena (CA): Arrowhead Pharmaceuticals, Inc.; 2026 Jan 6.

[7] Arrowhead Pharmaceuticals, Inc. ARO-INHBE and ARO-ALK7 interim clinical data update [Internet]. Arrowhead Pharmaceuticals, Inc.; 2026 Jan.

[8] Alnylam Pharmaceuticals. A study to evaluate ALN-2232 in participants with obesity [Internet]. Alnylam Pharmaceuticals. Clinical trial identifier: NCT07463846.

[9] Chen L, Xu J, Li J, Liu G, Ma H. Therapeutic oligonucleotides revisited: focus on siRNA and antisense technologies. The Innovation Drug Discovery. 2026;1(1):100007. doi: 10.59717/j.xinn-drugdisc.2026.100007.